Triple drug immunosuppression significantly reduces aortic allograft arteriosclerosis in the rat

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 4, 1996, Pages 553-564

  Lemström, Karl B ^a   Räisänen Sokolowski, Anne K ^a   Häyry, Pekka J ^a   Koskinen, Petri K ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

allograft; arteriosclerosis; chronic rejection; cyclosporine; rat

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA GRAFT; ARTERIOSCLEROSIS; ARTICLE; AUTORADIOGRAPHY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; GRAFT REJECTION; HELPER CELL; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; LEUKOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0029873284     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.4.553     Document Type: Article

References (48)

1. Kaye MP. The registry of The International Society for Heart and Lung Transplantation: Ninth Official Report 1992. J Heart Lung Transplant. 1992;11:599-606.
2. Barnart GR, Pascoe EA, Mills AC, Szentpetery S, Eich DM, Mohanakumar T, Hastillo A, Thompson JA, Hess ML, Lower RR. Accelerated coronary arteriosclerosis in cardiac transplant recipients. Transplant Rev. 1989;1:31-46.
3. Taylor DO, Ibrahim HM, Tolman DR, Hess ML. Accelerated coronary atherosclerosis in cardiac transplantation. Transplant Rev. 1991;5:165-174.
4. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol. 1988;12:334-340.
5. Olivari MT, Homans DC, Wilson RF, Kubo SH, Ring WS. Coronary artery disease in cardiac transplant patients receiving tripledrug immunosuppressive therapy. Circulation. 1989;80(suppl III):III-111-III-115.
6. Johnson DE, Alderman EL, Schroeder JS, Gao SZ, Hunt S, Decampli WM, Stinson E, Billingham M. Transplant coronary artery disease: histopathologic correlations with angiographic morphology. J Am Coll Cardiol. 1991;17:449-457.
7. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant. 1992;11:38-44.
8. Russell ME, Fujita M, Masek MA, Rowan RA, Billingham ME. Cardiac allograft vascular disease: nonselective involvement of large and small vessels. Transplantation. 1994;56:762-764.
9. Kahan BD. Cyclosporine. N Engl J Med. 1989;321:1725-1738.
10. Kronke M, Leonard WJ, Sepper JM, Arya SK, Wong-Staal F, Fallo RC, Waldmann TA, Greene WC. Cyclosporine A inhibits T-cell growth gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA. 1984;81:5214-5218.
11. Ilstad ST, Simmons RL. Biology of organ transplantation and immunosuppression. In: Starzl TE, Shapiro R, Simmons RL, eds. Atlas of Organ Transplantation. New York, NY: Gower Medical Publishing; 1991.
12. Schreiber SL, Grabtree GR. The mechanism of action of cyclosporine A and FK506. Immunol Today. 1992;13:136-142.
13. Erlanger BF. Do we know the site of action of Cyclosporine? Immunol Today. 1992;13:487-489.
14. Lee SW, Tsou AP, Chan H, Thomas J, Petrie K, Eugui EM, Allison AC. Glucocorticoids selectively inhibit the transcription of the interleukin 1 β gene and decrease the stability of interleukin 1 β mRNA. Proc Natl Acad Sci USA. 1988;85:1204-1208.
15. Bach JF. Thiopurines. The Mode of Action of Immunosuppressive Agents. New York, NY: American Elsevier Publishing Co; 1975:93-172.
16. Yilmaz S, Taskinen E, Paavonen T, Mennander A, Häyry P. Chronic rejection of rat renal allograft, I: histological differentiation between chronic rejection and Cyclosporine nephrotoxicity. Transpl Int. 1992;5:85-95.
17. Mennander A, Tiisala S, Halttunen J, Yilmaz S, Paavonen T, Häyry P. Chronic rejection in rat aortic allografts: an experimental model for transplant arteriosclerosis. Arterioscler Thromb. 1991;11:671-680.
18. Aherne WA, Dunnill MS. Morphometry. London, England: Edward Arnold; 1980.
19. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
20. Bhan AK. Immunoperoxidase. In: Colvin RB, Bhan AK, McCluskey RT, eds. Diagnostic Immunopathology. New York, NY: Raven Press; 1988.
21. Pipkin FB. Medical Statistics Made Easy. Edinburgh, Scotland: Churchill Livingstone; 1984.
22. Montgomery D, Peck E. Introduction to Linear Regression Analysis. New York, NY: John Wiley & Sons, Inc; 1982.
23. Mennander A, Tiisala S, Paavonen T, Halttunen J, Häyry P. Chronic rejection of rat aortic allograft, II: administration of cyclosporine induces accelerated allograft arteriosclerosis. Transpl Int. 1991;4:173-179.
24. Ferns G, Reidy M, Ross R. Vascular effects of cyclosporine A in vivo and in vitro. Am J Pathol. 1990;137:403-413.
25. Jonasson L, Holm J, Hansson GK. Cyclosporine A inhibits smooth muscle cell proliferation in the vascular response to injury. Proc Natl Acad Sci U S A. 1988;85:2303-2306.
26. Emeson EE, Shen M-L. Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporine A. Am J Pathol. 1994;142:1906-1915.
27. Thyberg J, Hansson GK. Cyclosporine A inhibits induction of DNA synthesis by PDGF and other peptide mitogens in cultured rat aortic smooth muscle cells and dermal fibroblasts. Growth Factors. 1991;4:209-219.
28. Leszczynski D, Zhao Y, Yeagley TJ, Foegh ML. Direct and endothelial cell-mediated effect of cyclosporine A on the proliferation of rat smooth muscle cells in vitro. Am J Pathol. 1993;142:149-155.
29. Zoja C, Furci L, Chilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporine-induced endothelial cell injury. Lab Invest. 1986;55:455-462.
30. Granelli-Piperno A. Lymphokine gene expression in vivo is inhibited by cyclosporine A. J Exp Med. 1990;171:533-544.
31. Nguyen DT, Eskandari MK, DeForge LE, Raiford CL, Stricter RM, Kunkel ST, Remick DG. Cyclosporine A modulation of tumor necrosis factor gene expression and effects in vitro and in vivo. J Immunol. 1990;144:3822-3828.
32. Reisman L, Cooper D, Lieberman KV, Martinelli GP. Cyclosporine suppresses IL-1 production by isolated human monocytes and by the human histiocytoma cell line, THP-1. Transplant Proc. 1990;22:1744-1746.
33. Demetris AJ, Lasky S, van Teil DH, Starzl TE, Dekker A. Pathology of hepatic transplantation: a review of 62 adult allograft recipients immunosuppressed with cyclosporine/steroid combination. Am J Pathol. 1985;118:151-158.
34. Herskowitz A, Tamura F, Ueda K, Neumann DA, Slepian M, Rose NR, Beschorner WE, Baumgartner WA, Reitz BR, Sell KW, Ahmed-Ansari A. Induction of donor major histocompatibility complex antigens in coronary arterial vessels: mechanism of arterial vasculitis in rat allografts treated with cyclosporine. J Heart Lung Transplant. 1989;8:11-19.
35. Palmer DC, Tsai CC, Roodman ST, Codd JE, Miller LW, Sarafian JE, Williams GA. Heart allograft arteriosclerosis: an ominous finding on endomyocardial biopsy. Transplantation. 1985;39:385-388.
36. Smith SH, Kirklin JK, Geer JC, Gaulfield JB, McGiffin DC. Arteritis in cardiac rejection after transplantation. Am J Cardiol. 1987;59:1171-1173.
37. Sommer BG, Innes JT, Whitehurst RM, Sharma HM, Ferguson RM. Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. Am J Surg. 1985;149:759-764.
38. Schmitz-Rixen T, Megerman J, Colvin RB, Williams AM, Abbott WM. Immunosuppressive treatment of aortic allografts. J Vasc Surg. 1988;7:82-92.
39. Plissonier D, Amichot G, Lecagneux J, Duriez M, Gentric D, Michel J-B. Additive and synergistic effects of a low-molecular-weight, heparin-like molecule and low doses of cyclosporine in preventing arterial rejection in rats. Arterioscler Thromb. 1993;13: 112-119.
40. Andersen HØ, Madsen G, Nordestgaard BG, Hansen BF, Kjeldsen K, Stander S. Cyclosporine suppresses transplant arteriosclerosis in the aorta-allografted, cholesterol-clamped rabbit: suppression preceded by decrease in arterial lipoprotein permeability. Arterioscler Thromb. 1994;14:944-950.
41. Koskinen PK, Lemström KB, Häyry PJ. How cyclosporine modifies histological and molecular events in the vascular wall during chronic rejection of rat cardiac allografts. Am J Pathol. 1995;146:972-980.
42. Lurie KG, Billingham ME, Jamieson SW, Harrison DC, Reitz BA. Pathogenesis and prevention of graft arteriosclerosis in an experimental heart transplant model. Transplantation. 1981;31:41-47.
43. Meiser BM, Billingham ME, Morris RE. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet. 1991;338:1297-1298.
44. Guttman RD, Forbes RDC, Zheng S, Busque S. Cyclosporine and the reversibility of chronic vascular rejection in a rat model: the Third International Congress on Cyclosporine, Seville, Spain. Transplant Proc. In press.
45. Handa N, Hatanaka M, Baumgartner WA, Reitz B, Sandford G, Esa AH, Herskowitz A. Late cyclosporine treatment ameliorates established coronary graft disease in rat allograft. Transplantation. 1993;56:535-540.
46. Libby P, Salomon RN, Payne DD, Schoen FJ, Pober JS. Functions of vascular wall cells related to the development of transplantation-associated coronary arteriosclerosis. Transplant Proc. 1989;21:3677-3684.
47. Hruban RH, Beschorner WE, Baumgartner WA, Augustine SM, Ren H, Reitz BA, Hutchins GM. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am J Pathol. 1990;137:871-882.
48. Salomon RN, Hughes CCW, Schoen FJ, Payne DD, Pober JS, Libby P. Human coronary transplantation-associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol. 1991;138:791-798.